New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

Baptist GallwitzDept Medicine IV, Tübingen University, Otfried-Müller-Str, 10, 72076 Tübingen, GermanyAbstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Gallwitz B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	type 2 diabetes diabetes therapy DPP-IV inhibitors incretin based therapy GLP-1 saxagliptin Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/59aefce73bca42f689f11d9de1343e7b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:59aefce73bca42f689f11d9de1343e7b
record_format	dspace
spelling	oai:doaj.org-article:59aefce73bca42f689f11d9de1343e7b2021-12-02T00:15:33ZNew treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin1178-7007https://doaj.org/article/59aefce73bca42f689f11d9de1343e7b2010-05-01T00:00:00Zhttps://www.dovepress.com/new-treatments-in-the-management-of-type-2-diabetes-a-critical-apprais-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Baptist GallwitzDept Medicine IV, Tübingen University, Otfried-Müller-Str, 10, 72076 Tübingen, GermanyAbstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It is highly selective for DPP-4 in comparison to other enzymes of the dipeptidyl peptidase family. DPP-4 inhibitors elevate plasma concentrations of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This effect results in a glucose-dependent stimulation of insulin secretion and an inhibition of glucagon secretion without an intrinsic risk for hypoglycemia. In comparison to sulfonylureas and thiazolidinediones that promote weight gain, DPP-4 inhibitors are weight neutral. Saxagliptin has been approved by the FDA for the US and by the EMEA for Europe in 2009. Clinical trials showed a dose-dependent inhibition of DPP-4 by saxagliptin in doses ranging from 2.5 to 100 mg daily without serious side effects. Type 2 diabetic patients receiving 5 mg to 10 mg saxagliptin once daily had a significant lowering of HbA1c and glycemic parameters along with good tolerability and safety. Saxagliptin has demonstrated a good efficacy for glycemic parameters in various patient populations either in monotherapy or in combination with metformin and other oral antidiabetic drugs as well as a favorable cardiovascular profile. With its high selectivity for DPP-4 and its clinical and cardiovascular profile, saxagliptin is an attractive novel DPP-4 inhibitor.Keywords: type 2 diabetes, diabetes therapy, DPP-4 inhibitors, incretin based therapy, GLP-1, saxagliptinGallwitz BDove Medical Pressarticletype 2 diabetesdiabetes therapyDPP-IV inhibitorsincretin based therapyGLP-1saxagliptinSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 117-124 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	type 2 diabetes diabetes therapy DPP-IV inhibitors incretin based therapy GLP-1 saxagliptin Specialties of internal medicine RC581-951
spellingShingle	type 2 diabetes diabetes therapy DPP-IV inhibitors incretin based therapy GLP-1 saxagliptin Specialties of internal medicine RC581-951 Gallwitz B New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
description	Baptist GallwitzDept Medicine IV, Tübingen University, Otfried-Müller-Str, 10, 72076 Tübingen, GermanyAbstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It is highly selective for DPP-4 in comparison to other enzymes of the dipeptidyl peptidase family. DPP-4 inhibitors elevate plasma concentrations of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This effect results in a glucose-dependent stimulation of insulin secretion and an inhibition of glucagon secretion without an intrinsic risk for hypoglycemia. In comparison to sulfonylureas and thiazolidinediones that promote weight gain, DPP-4 inhibitors are weight neutral. Saxagliptin has been approved by the FDA for the US and by the EMEA for Europe in 2009. Clinical trials showed a dose-dependent inhibition of DPP-4 by saxagliptin in doses ranging from 2.5 to 100 mg daily without serious side effects. Type 2 diabetic patients receiving 5 mg to 10 mg saxagliptin once daily had a significant lowering of HbA1c and glycemic parameters along with good tolerability and safety. Saxagliptin has demonstrated a good efficacy for glycemic parameters in various patient populations either in monotherapy or in combination with metformin and other oral antidiabetic drugs as well as a favorable cardiovascular profile. With its high selectivity for DPP-4 and its clinical and cardiovascular profile, saxagliptin is an attractive novel DPP-4 inhibitor.Keywords: type 2 diabetes, diabetes therapy, DPP-4 inhibitors, incretin based therapy, GLP-1, saxagliptin
format	article
author	Gallwitz B
author_facet	Gallwitz B
author_sort	Gallwitz B
title	New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
title_short	New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
title_full	New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
title_fullStr	New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
title_full_unstemmed	New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
title_sort	new treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/59aefce73bca42f689f11d9de1343e7b
work_keys_str_mv	AT gallwitzb newtreatmentsinthemanagementoftype2diabetesacriticalappraisalofsaxagliptin
_version_	1718403867922661376

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

Ejemplares similares